This site is intended for health professionals only
Monday 20 May 2019
Share |

CHMP backs Rienso for iron-deficiency anaemia

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the use of Rienso injection to treat iron-deficiency anaemia in patients with chronic kidney disease (CKD).

The Committee has recommended granting marketing authorisation for the treatment as a 30mg/ml solution for intravenous injection.

The diagnosis of iron deficiency must be based on

appropriate laboratory tests. 

The applicant for marketing authorisation of this medicinal product is Takeda Global Research and Development Centre (Europe) Ltd. 

The active substance of Rienso is Ferumoxytol, a colloidal iron-carbohydrate complex. Upon release from the complex, the iron either enters the intracellular storage iron pool (e.g., ferritin) or is

transferred to plasma transferrin for transport to erythroid precursor cells for incorporation into haemoglobin.

The benefits with Rienso are its ability to increase haemoglobin levels. 

The most common side effects are diarrhoea, nausea, constipation, headache, dizziness and hypotension.

A pharmacovigilance plan for Rienso will be implemented as part of the marketing authorisation.

European Medicines Agency

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher